Presentation is loading. Please wait.

Presentation is loading. Please wait.

BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro. BRAF-mutant melanoma cells are resistant to the antigrowth.

Published byHege Knutsen Modified over 5 years ago

Similar presentations

Presentation on theme: "BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro. BRAF-mutant melanoma cells are resistant to the antigrowth."— Presentation transcript:

1 BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro.
BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro. A, colony formation for D04, MM415, MM485, WM1366, WM852, A375, MDA-MB-435, Mel-HO, SK-Mel28, and WM cells in soft-agar in the presence of metformin (Met; 2 mmol/L) and AICAR (1 mmol/L). Colony numbers are represented relative to dimethyl sulfoxide (DMSO)–treated controls (%). Error bars, SD from the mean (n = 3). B–D, Western blot for phospho-AMPKα (pAMPKα), phospho-ACC (pACC), and total AMPKα (loading control) in SK-Mel28 (B), A375 (C), and D04 cells (D) treated with AICAR (1 mmol/L) for the times indicated in hours. Matthew J. Martin et al. Cancer Discovery 2012;2: ©2012 by American Association for Cancer Research

Download ppt "BRAF-mutant melanoma cells are resistant to the antigrowth effects of metformin and AICAR in vitro. BRAF-mutant melanoma cells are resistant to the antigrowth."

Similar presentations

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.

Effects of BRG1 depletion in the proliferation of lung cancer cells with amplification at the MYC family of genes and in MAX-deficient cells, after reconstitution.
Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.

Fig. 2. Effects of AZD4785 on proliferation and MAPK pathway signaling in KRAS mutant and wild-type cancer cells in vitro. Effects of AZD4785 on proliferation.
Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.

Genetic alterations in the PI3K–PTEN–AKT pathway detected during disease progression and their functional impacts. Genetic alterations in the PI3K–PTEN–AKT.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Volume 33, Issue 2, Pages (January 2009)

Volume 33, Issue 2, Pages (January 2009)
Cellular activity and selectivity of ARS-853.

Cellular activity and selectivity of ARS-853.
Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.

Proline supplementation during P5CS protein knockdown suppressed GCN2 activation. Proline supplementation during P5CS protein knockdown suppressed GCN2.
Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.

Bortezomib sensitivity correlates with basal NF-κB activity in KP lung adenocarcinoma cell lines. Bortezomib sensitivity correlates with basal NF-κB activity.
The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.

The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma cells. The EGF receptor confers BRAF inhibitor resistance in BRAF-mutant melanoma.
Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.

Fig. 1. Drug combination screen identifies BETi as acting synergistically with PARPi. Drug combination screen identifies BETi as acting synergistically.
Interfering with HMGA2 expression blocks transformation in metastatic lung cancer cells. Interfering with HMGA2 expression blocks transformation in metastatic.

Interfering with HMGA2 expression blocks transformation in metastatic lung cancer cells. Interfering with HMGA2 expression blocks transformation in metastatic.
Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.
BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.
Fig. 3. TKI sensitivity assessed by the MANO method.

Fig. 3. TKI sensitivity assessed by the MANO method.
BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.

BRAF inhibitor-resistant BRAF-mutant melanoma cells show increased invasion and metastatic potential. BRAF inhibitor-resistant BRAF-mutant melanoma cells.
AMPK induces VEGF-A production by upregulating ERK signaling.

AMPK induces VEGF-A production by upregulating ERK signaling.
A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.

A and B, CO-1686–resistant NCI-H1975 cell clones, COR1-1 and COR10-1 display a reduced dependence on EGFR signaling for survival. A and B, CO-1686–resistant.
The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL

The role of SRC-C3G-RAP1 signaling in transformation induced by CRKL
Matthew A. Will, M. D. , Murugesan Palaniappan, Ph. D

Matthew A. Will, M. D. , Murugesan Palaniappan, Ph. D

Similar presentations

Ads by Google